Depending on what you're talking about, as I explained, about 80% of the biotechnology companies currently in Canada are SMEs. We define that as small and medium enterprises of less than 50 employees. A lot of these companies are facing two challenges.
Number one is that they were typically started by a scientist who may not necessarily have the business acumen to attract capital investment and who is wearing a multitude of hats.
Number two is that they are companies that typically have a research and development cycle that is very long and not very politically sustainable. I use that term to mean that it doesn't get political awards within a political mandate of four years. A lot of the time, though, they are a sector that can reap long-term rewards a great deal for a country. Within a short-term mandate, it's very difficult to get anything tangible out the door within three or four years.
The challenges they are facing right now are capital investment and being able to sustain. They are burning up capital as fast as it is coming in the door.